• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Severe infusion reaction due to nivolumab: A case report.纳武利尤单抗致严重输注反应：1 例报告。
Cancer Rep (Hoboken). 2020 Jun;3(3):e1246. doi: 10.1002/cnr2.1246. Epub 2020 May 4.
2
Treatment with pembrolizumab after hypersensitivity reaction to nivolumab in a patient with hepatocellular carcinoma.患者肝癌对纳武利尤单抗发生超敏反应后，使用帕博利珠单抗治疗。
Am J Health Syst Pharm. 2019 Oct 15;76(21):1749-1752. doi: 10.1093/ajhp/zxz189.
3
Extensive-Stage Small-Cell Lung Cancer With Sustained Complete Response to Single-Agent Nivolumab and Immune-Related Dermatitis.广泛期小细胞肺癌对单药纳武单抗持续完全缓解并伴有免疫相关皮炎
Clin Lung Cancer. 2020 Jan;21(1):e6-e9. doi: 10.1016/j.cllc.2019.09.005. Epub 2019 Sep 26.
4
Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program.免疫相关不良反应与接受纳武利尤单抗治疗的 NSCLC 患者的临床结局相关：意大利 NSCLC 扩大准入项目。
Lung Cancer. 2020 Feb;140:59-64. doi: 10.1016/j.lungcan.2019.12.014. Epub 2019 Dec 20.
5
Nivolumab for the treatment of Japanese patients with advanced metastatic non-small cell lung cancer: a review of clinical trial evidence for efficacy and safety.纳武利尤单抗治疗晚期转移性非小细胞肺癌的日本患者：疗效和安全性临床试验证据的综述。
Ther Adv Respir Dis. 2018 Jan-Dec;12:1753466618801167. doi: 10.1177/1753466618801167.
6
Nivolumab-associated Stevens-Johnson syndrome in a patient with lung cancer.纳武利尤单抗相关的史蒂文斯-约翰逊综合征 1 例合并肺癌患者
Dermatol Online J. 2021 Mar 15;27(3):13030/qt2897t6dq.
7
Safety profile of nivolumab administered as 30-min infusion: analysis of data from CheckMate 153.纳武利尤单抗 30 分钟输注的安全性特征：CheckMate 153 数据分析。
Cancer Chemother Pharmacol. 2018 Apr;81(4):679-686. doi: 10.1007/s00280-018-3527-6. Epub 2018 Feb 13.
8
Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report.免疫检查点抑制剂（纳武利尤单抗）相关肾损伤以及识别已知可引起急性肾小管间质性肾炎的伴随用药的重要性：一例报告
BMC Nephrol. 2018 Feb 27;19(1):48. doi: 10.1186/s12882-018-0848-y.
9
Widespread Nivolumab-induced Enteropathy in a Long Responder Non-Small-cell Lung Cancer Patient.一名长期缓解的非小细胞肺癌患者中广泛发生的纳武利尤单抗诱导的肠病
Clin Lung Cancer. 2018 Sep;19(5):e591-e596. doi: 10.1016/j.cllc.2018.04.013. Epub 2018 May 5.
10
Late Gastrointestinal Toxicity During Nivolumab Therapy in Non-Small Cell Lung Cancer: A Rare Case of Inflammatory Bowel Disease.纳武单抗治疗非小细胞肺癌期间的晚期胃肠道毒性：一例罕见的炎症性肠病病例
J Thorac Oncol. 2018 Aug;13(8):e152-e153. doi: 10.1016/j.jtho.2018.03.022.

引用本文的文献

1
Case report: Pembrolizumab as an alternative to atezolizumab following a severe infusion reaction.病例报告：在严重输液反应后，派姆单抗作为阿特珠单抗的替代药物。
Front Oncol. 2024 Mar 4;14:1273043. doi: 10.3389/fonc.2024.1273043. eCollection 2024.
2
A Case of Nonsmall-Cell Lung Cancer with Anaphylaxis after 41 Courses of Pembrolizumab along with Adrenal Insufficiency as an Immune-Related Adverse Event.一例接受41个疗程帕博利珠单抗治疗后发生过敏反应并伴有肾上腺功能不全这一免疫相关不良事件的非小细胞肺癌病例。
Case Rep Oncol. 2022 Sep 19;15(3):804-808. doi: 10.1159/000526561. eCollection 2022 Sep-Dec.
3
Nivolumab Hypersensitivity Reactions a Myth or Reality in Solid Tumors-A Systematic Review of the Literature.纳武利尤单抗过敏反应：实体瘤中的臆想还是现实——文献系统综述。
Curr Oncol. 2022 Dec 2;29(12):9428-9436. doi: 10.3390/curroncol29120741.

本文引用的文献

1
Treatment with pembrolizumab after hypersensitivity reaction to nivolumab in a patient with hepatocellular carcinoma.患者肝癌对纳武利尤单抗发生超敏反应后，使用帕博利珠单抗治疗。
Am J Health Syst Pharm. 2019 Oct 15;76(21):1749-1752. doi: 10.1093/ajhp/zxz189.
2
Cytokine release syndrome.细胞因子释放综合征。
J Immunother Cancer. 2018 Jun 15;6(1):56. doi: 10.1186/s40425-018-0343-9.
3
Nivolumab infusion reaction manifesting as plantar erythema and pulmonary infiltrate in a lung cancer patient.纳武利尤单抗输注反应表现为肺癌患者足底红斑和肺部浸润。
Thorac Cancer. 2017 Nov;8(6):706-709. doi: 10.1111/1759-7714.12494. Epub 2017 Aug 28.
4
Severe cytokine release syndrome in a patient receiving PD-1-directed therapy.一名接受PD-1靶向治疗的患者出现严重细胞因子释放综合征。
Pediatr Blood Cancer. 2017 Dec;64(12). doi: 10.1002/pbc.26642. Epub 2017 May 24.
5
First case of allergy to nivolumab.
J Allergy Clin Immunol Pract. 2017 Jul-Aug;5(4):1140-1141. doi: 10.1016/j.jaip.2017.01.015. Epub 2017 Mar 9.
6
Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy.抗 PD-1 抗体治疗相关免疫相关不良药物反应的诊断、监测和管理。
Cancer Treat Rev. 2016 Apr;45:7-18. doi: 10.1016/j.ctrv.2016.02.003. Epub 2016 Feb 18.
7
Drug hypersensitivity reactions: pathomechanism and clinical symptoms.药物过敏反应：发病机制和临床症状。
Med Clin North Am. 2010 Jul;94(4):645-64, xv. doi: 10.1016/j.mcna.2010.04.003.

纳武利尤单抗致严重输注反应：1 例报告。

Severe infusion reaction due to nivolumab: A case report.

机构信息

Medical Oncology Department, Nepean Hospital Cancer Care Centre, Kingswood, New South Wales, Australia.

Medical Oncology Department, Westmead Hospital Crown Princess Mary Cancer Centre, Westmead, New South Wales, Australia.

出版信息

Cancer Rep (Hoboken). 2020 Jun;3(3):e1246. doi: 10.1002/cnr2.1246. Epub 2020 May 4.

DOI:10.1002/cnr2.1246
PMID:32671983
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7941420/
Abstract

BACKGROUND

Nivolumab is an anti-PD1 immune checkpoint inhibitor commonly used for the treatment of solid organ and hematological malignancies. Severe infusion reaction due to nivolumab is quite rare.

CASE

We report a case of severe infusion reaction due to nivolumab necessitating ICU admission and withdrawal of further nivolumab use in a patient with metastatic non-small cell lung cancer.

CONCLUSION

Our knowledge and expertise with the use of immune checkpoint inhibitors are still evolving. This report highlights one of the rare possible side-effects that clinicians and patients may have to face with increasing indications and use of nivolumab in day to day practice.

摘要

背景

尼伏鲁单抗是一种抗 PD-1 免疫检查点抑制剂，常用于治疗实体器官和血液系统恶性肿瘤。由于尼伏鲁单抗引起的严重输注反应相当罕见。

病例

我们报告了一例转移性非小细胞肺癌患者因尼伏鲁单抗引起的严重输注反应，需要入住 ICU 并停止进一步使用尼伏鲁单抗。

结论

我们对免疫检查点抑制剂的使用的了解和专业知识仍在不断发展。本报告强调了随着尼伏鲁单抗在日常实践中的应用不断增加，临床医生和患者可能不得不面对的一种罕见的可能副作用。